

Jaguar Health, Inc.
Form 8-K
April 04, 2019

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **March 29, 2019**

JAGUAR HEALTH, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation)

001-36714
(Commission File Number)

46-2956775
(IRS Employer Identification No.)

201 Mission Street, Suite 2375
San Francisco, California
(Address of principal executive offices)

94105
(Zip Code)

Edgar Filing: Jaguar Health, Inc. - Form 8-K

Registrant's telephone number, including area code: **(415) 371-8300**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 1.01 Entry into a Material Definitive Agreement.

As previously disclosed, on August 28, 2018, Jaguar Health, Inc. (the **Company**) entered into an Office Lease Agreement (the **Lease**) with CA-Mission Street Limited Partnership, a Delaware limited partnership (**Landlord**), to extend the **Company**'s lease for approximately 6,311 square feet of office space located at 201 Mission Street, Suite 2375, San Francisco, California (the **Premises**). Concurrently with the execution of this Lease, the **Company** was required to deliver to the **Landlord** a standby, unconditional, irrevocable, transferable letter of credit, naming **Landlord** as beneficiary, as collateral for the full performance by the **Company** of all of its obligations under the Lease and for all losses and damages **Landlord** may suffer as a result of the **Company**'s failure to comply with one or more provisions of the Lease.

To satisfy the letter of credit requirement in the Lease, Pacific Capital Management, LLC (the **LC Facilitator**), one of the **Company**'s existing shareholders, caused its financial institution to issue a letter of credit in the amount of \$475,000 (the **Landlord Letter of Credit**) on behalf of the **Company** in favor of **Landlord** pursuant to the terms of the **Landlord Letter of Credit & Warrant Issuance Agreement**, dated August 28, 2018, by and between the **Company** and the **LC Facilitator** (**Landlord LOC Agreement**). Under the terms of the **Landlord LOC Agreement**, the **Company** was required to cause **LC Facilitator**'s exposure under the **Landlord Letter of Credit** to be reduced by \$122,000 (the **Reduced Exposure Obligation**). The **Company** caused its financial institution, Western Alliance Bank (the **Issuing Bank**), to issue a letter of credit in the amount of \$122,000 in favor of the letter of credit beneficiary (**LC Beneficiary**), who is the managing member of the **LC Facilitator**, pursuant to the terms of the **Irrevocable Standby Letter of Credit No. LC22120-602**, dated December 13, 2018 signed by the **Issuing Bank** (the **LC Beneficiary Letter of Credit**) in order to reduce **LC Facilitator**'s exposure under the **Landlord Letter of Credit**.

On March 29, 2019, the **Company** and the **LC Beneficiary** entered in a letter of credit cancellation and warrant issuance agreement (**LOC Cancellation and Warrant Issuance Agreement**), pursuant to which **LC Beneficiary** agreed to cancel the **LC Beneficiary Letter of Credit** and terminate the **Company**'s **Reduced Exposure Obligation** in consideration for the **Company**'s issuance of a 5-year warrant (the **LOC Warrant**) to purchase shares of the **Company**'s common stock (**Common Stock**) in an amount equal to 75% of the principal amount of **Reduced Exposure Obligation** divided by the **Exercise Price** (as defined below). The exercise price for the **LOC Warrant** (the **Exercise Price**) is the price per share at which the **Company** issues **Common Stock** in its next underwritten public offering (the **Public Offering**), provided that if the **Company** has not consummated a **Public Offering** by the four-month anniversary of the issuance date of the **LOC Warrant**, then the exercise price will be equal to the closing sales price of the **Common Stock** on the four-month anniversary of the issuance date of the **LOC Warrant**, in each case subject to adjustment for reclassification of the **Common Stock**, non-cash dividend, stock split, reverse stock split or other similar transaction.

The foregoing summary of the terms of the **LOC Warrant** and the **LOC Cancellation and Warrant Issuance Agreement** do not purport to be complete and are qualified in its entirety by reference to the form of **LOC Warrant** and the **LOC Cancellation and Warrant Issuance Agreement**, copies of which are filed as Exhibits 4.1 and 10.1, respectively, to this Form 8-K and are incorporated herein by reference.

Item 3.02 Unregistered Sales of Equity Securities.

All of the securities described in this Current Report on Form 8-K were offered and sold in reliance upon exemptions from registration pursuant to 4(a)(2) under the Securities Act of 1933, as amended (**Securities Act**), and Rule 506 of Regulation D promulgated thereunder. The offering was made to an accredited investor (as defined by Rule 501 under the Securities Act).

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

| Exhibit No. | Description |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 4.1 | <u>Form of LOC Common Stock Warrant.</u> |
| 10.1 | <u>Letter of Credit Cancellation & Warrant Issuance Agreement, dated March 29, 2019, by and between Jaguar Health, Inc. and the letter of credit beneficiary named therein.</u> |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

JAGUAR HEALTH, INC.

By: /s/ Karen S. Wright
Name: Karen S. Wright
Title: Chief Financial Officer

Date: April 4, 2019